The goal of this clinical trial is to learn whether diaphragmatic biofeedback added to respiratory muscle training improves clinical and functional outcomes in adults with chronic kidney disease. It will also evaluate the feasibility and acceptability of this intervention. The main questions it aims to answer are: Is diaphragmatic biofeedback added to respiratory muscle training acceptable and well tolerated in patients with chronic kidney disease? Does this intervention reduce respiratory symptoms and complications in this population? Does diaphragmatic biofeedback added to respiratory muscle training improve cardiorespiratory capacity and quality of life? Researchers will evaluate diaphragmatic biofeedback combined with respiratory muscle training and a placebo intervention based on conscious breathing to assess its effects. Participants will: * Perform the assigned intervention three times per day for 6 weeks * Follow a structured respiratory muscle training program with diaphragmatic biofeedback * Be monitored for symptoms, respiratory complications, and perceived quality of life throughout the study
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of participants with treatment-related adverse events during intervention sessions
Timeframe: Baseline to 6 weeks
Respiratory Symptoms assessed by Edmonton Symptom Assessment Scale (ESAS)
Timeframe: Baseline to 6 weeks
Respiratory Complications
Timeframe: Baseline to 12 weeks
Quality of Life of participants evaluated by Euqol-5Dimensions questionnaire
Timeframe: Baseline to 6 weeks
Acceptability of intervention considering number of sessions completed by participant
Timeframe: 6 weeks